RG 7636

Drug Profile

RG 7636

Alternative Names: DEDN-6526A; RG7636

Latest Information Update: 03 Nov 2015

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 24 Jul 2014 Discontinued - Phase-I for Malignant melanoma in Australia (IV) (Roche pipeline)
  • 24 Jul 2014 Discontinued - Phase-I for Malignant melanoma in USA (IV) (Roche pipeline)
  • 20 Jan 2013 Genentech resumes enrolment in a phase I trial for Malignant melanoma in USA and Australia (NCT01522664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top